Skip to main content
Premium Trial:

Request an Annual Quote

Volpara Solutions, Ambry Genetics Form Breast Cancer Management Alliance

NEW YORK — Volpara Health Technologies said on Wednesday that its Volpara Solutions subsidiary has signed an agreement to link its cancer screening and practice management platform with Ambry Genetics' program for identifying high-risk breast cancer patients.

Under the terms of the deal, Volpara's Aspen Breast software for medical practice management will include an online ordering process for Ambry's genetic tests. Meanwhile, Volpara's Density software for assessing volumetric breast density will be included in Ambry's Comprehensive, Assessment, Risk, and Education (CARE) program, which uses risk assessment models and genetic testing to identify high-risk women and guide future screening and treatment decisions.

Additional terms were not disclosed.

About a year ago, Wellington, New Zealand-based Volpara Health Solutions acquired Lynnwood, Washington-based Medical Reporting Systems, which developed Aspen Breast. Aliso Viejo, California-based Ambry is a unit of Japan's Konica Minolta.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.